Ixiaro was developed to provide a well-tolerated, effective and convenient vaccine against Japanese encephalitis (JE), suitable for administration to travelers who wish to reduce their risk of acquiring the disease, the company said.
Ixiaro was developed by Intercell. Novartis and Intercell have a strategic alliance based on a shared vision of science in vaccines R&D. The alliance provides Novartis with the development and commercialization rights to Intercell’s entire non-partnered early state vaccines pipeline.
Andrin Oswald, CEO of Novartis Vaccines and Diagnostics, said: “Asia is now the second most popular travel destination globally, and travel to the region is expected to increase. JE is spread by mosquitoes, which makes it unpredictable. Vaccination is the most effective preventive measure against the disease.”